Amedisys Inc (AMED) Return on Equity ROE from the second quarter 2025 to second quarter 2024 and annually, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Amedisys Inc  (NASDAQ: AMED)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare

Amedisys Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Amedisys Inc in the second quarter 2025?
Amedisys Inc achieved a return on average equity (ROE) of 6.68 % in its second quarter 2025, this is above AMED's average return on equity of 6.26%.
Amedisys Inc shareholder's equity over the 12 months ending in its second quarter 2025 are valued at $1,225 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Healthcare Facilities industry 19 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2025 from 1576 to 1796.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Equity Change 8.14 % 8.96 % 5.37 % 9.78 % -
Y / Y Net Income Change -10.81 % 323.61 % - -35.53 % -
Net Income (TTM) in Millions 82 85 38 83 92
Return On Equity (TTM) 6.68 % 7.11 % 3.25 % 7.13 % 8.1 %
AMED's Total Ranking # 1796 # 1576 # 2027 # 1548 # 1259
Equity (TTM) in Millions 1,275 1,245 1,180 1,200 1,179
Seq. Equity Change 2.4 % 5.52 % -1.71 % 1.83 % 3.17 %
Seq. Net Income Change -53.01 % - - -49.3 % 123.19 %

Back to AMED Management Effectiveness >> AMED's 5 Years Annual ROE >> Compare AMED ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 20
Sector # 144
Overall # 1796

Return On Equity Statistics
High Average Low
30.79 %
6.26 %
-47.71 %
(Jun 30 2021)   (Sep 30 2013)





AMED Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 1,180 1,120 1,107 976 811
Y / Y Equity Change 5.37 % 1.19 % 13.34 % 20.42 % 26.38 %
Net Income in Millions 38 -11 118 210 185
Y / Y Net Income Change - - -44 % 13.49 % 44.78 %
Return On Equity 3.23 % -0.98 % 10.64 % 21.53 % 22.84 %

Back to AMED Management Effectiveness >> AMED's 5 Years Annual ROE >> Compare AMED ROE to its Competitors




Annual Roe Comment
In 2024 ROE improved to 3.23 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Healthcare Facilities Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AMED's' Return on Equity at Yahoo Finance
AMED's Roe Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AMED's Competitors
Subscribers only: Roe for Amedisys Inc's Suppliers
Subscribers only: Return On Equity for AMED's Customers




Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector ROE
Stoke Therapeutics Inc   18.32 %
Amphastar Pharmaceuticals Inc   18.15 %
Phibro Animal Health Corporation  18.10 %
Engene Therapeutics Inc   17.71 %
West Pharmaceutical Services Inc   17.66 %
Electromed Inc   17.41 %
Semler Scientific inc   17.21 %
Ensign Group Inc  17.14 %
Cryoport inc   16.84 %
Aurinia Pharmaceuticals Inc   16.72 %
Mimedx Group Inc   16.22 %
Royalty Pharma Plc  16.11 %
Cormedix Inc   15.96 %
Collegium Pharmaceutical Inc   15.60 %
Intuitive Surgical Inc   15.59 %
Option Care Health Inc   15.25 %
Krystal Biotech Inc   15.21 %
Regeneron Pharmaceuticals Inc   15.11 %
Nephros Inc   14.89 %
Protalix Biotherapeutics inc   14.70 %
Quest Diagnostics Inc  14.40 %
Caredx Inc   14.27 %
Pediatrix Medical Group Inc   14.09 %
Stryker Corp  14.08 %
Lemaitre Vascular Inc   13.67 %
Neurocrine Biosciences Inc   13.22 %
Alpha Pro Tech Ltd   13.10 %
Black Diamond Therapeutics Inc   12.70 %
Penumbra Inc  12.41 %
Cadre Holdings inc   12.08 %

Date modified: 2026-06-22T14:32:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.